REVOLUTIONIZING DRUG DEVELOPMENT: THE SYNERGY OF AI AND BIOINFORMATICS IN SHAPING FUTURE THERAPEUTICS- A REVIEW

The combination of bioinformatics and AI improves the precision and productivity of medication development. Artificial intelligence (AI)-powered tools such as AlphaFold and Atomwise speed up the discovery process, and natural language processing (NLP) helps with literature mining and medication repurposing. Advanced approaches such as automated drug testing and quantum computing are also being studied. Despite challenges such as legal constraints and data quality difficulties, the report emphasizes the potential for these technologies to alter precision medicine in the future. This review looks at how bioinformatics and artificial intelligence are altering the pharmaceutical sector. Especially for complex diseases such as neurodegenerative disorders, conventional drug development approaches are costly, time-consuming, and yield low-quality results. AI methods such as machine learning (ML) and deep learning (DL) significantly speed up drug discovery by predicting drug-target interactions, optimizing drug design, and analyzing ADMET profiles. Meanwhile, bioinformatics facilitates the understanding of biological data by means of the analysis of proteomic, metabolomic, and genomic data. This allows greater precision.